Ryan Castillo: Jordan, heads up — I actually did some pre-reading on this one and I'm already skeptical, so you're going to have to work for it today.
Jordan Hale: Good, I want you skeptical, because the claim sounds almost too clean. Like, I was on a flight back from a work thing, opened my laptop at 35,000 feet, and the VOGUE results were just... sitting in my inbox. And I read the headline three times because I kept thinking I was misreading it.
Ryan Castillo: What was the headline?
Jordan Hale: Essentially: two HIV drugs just matched three, in patients who had never taken antiretrovirals before. This is coming out of AIDS 2026 — the 26th International AIDS Conference, Rio de Janeiro — and the trial is the VOGUE study. 509 treatment-naïve adults, randomized. Dovato, ViiV Healthcare's two-drug regimen, against Biktarvy, which is Gilead's three-drug pill, the one with over half the global HIV treatment market.
Ryan Castillo: And what was the result at Week 48?
Jordan Hale: Non-inferiority met. Dovato proved it was not worse than Biktarvy. Which sounds like a low bar until you realize — I mean, wait, no, let me say this right — treatment-naïve patients are the hardest test. You're not switching someone who's already suppressed. You're starting from scratch.
Ryan Castillo: Two cylinders doing the same work as three. Is that the right mental model?
Jordan Hale: That's exactly it. Same destination, same 48-week result, one fewer moving part — and ViiV Healthcare, which is majority owned by GSK with Shionogi as a shareholder, is the company that just made that case in front of the entire global HIV research community.
Ryan Castillo: But 'same destination' is doing a lot of heavy lifting there. Non-inferiority doesn't mean equivalent. It means not worse by a pre-specified margin — a margin ViiV chose before the trial started. That's not a small distinction.
Jordan Hale: Wait, so they set the bar themselves?
Ryan Castillo: That's how non-inferiority trials work. You define how much worse is acceptable before you enroll patient one. If Dovato lands inside that window, you declare success. Which they did. But 'inside the window' and 'just as good' are not the same sentence.
Jordan Hale: Okay but — I mean, here's what makes me push back on the cynical read. The population in VOGUE wasn't curated. Nearly half — 47% — came in with viral loads at or above 100,000 copies per mL. That's high. And 16% had low CD4+ counts, which is exactly the group clinicians historically didn't want to start on two drugs. If this were a cherry-picked trial, those people wouldn't be in it.
Ryan Castillo: No, that actually does strengthen the result — I'll give you that. Harder population, same outcome. And no treatment-emergent resistance in either arm at Week 48, which matters.
Jordan Hale: Right — but the part that doesn't fit is PASO DOBLE. Because that trial exists.
Ryan Castillo: GeSIDA 11720, yeah. That's the one people keep conflating with VOGUE, and they're completely different clinical questions. PASO DOBLE enrolled virologically suppressed adults who were switching regimens — not starting fresh. And it showed a 1.4% efficacy gap favoring Biktarvy at 48 weeks.
Jordan Hale: So we're not even talking about the same patient. Like, a suppressed switcher versus someone who's never taken a drug in their life — those are, you know, fundamentally different clinical bets.
Ryan Castillo: Exactly — and starting treatment-naïve is the harder bar. Which is why VOGUE is genuinely meaningful. I'm not dismissing it. I'm just saying meaningful and practice-changing are not the same word, and right now I don't see what closes that gap.
Jordan Hale: And that gap — between meaningful and practice-changing — what closes it? The honest answer is: almost nothing closes it fast. Picture a clinician at a busy urban HIV clinic. She has 400 patients on Biktarvy. Five years of watching it work. She reads the VOGUE abstract on a Friday afternoon, last patient just walked out. It says 'non-inferior.' She is not picking up the phone to switch anyone.
Ryan Castillo: Because there's no structural signal telling her to. No DHHS update, no IAS-USA guidance, no BHIVA commentary. Nothing.
Jordan Hale: Which is — I mean, that's the mechanism, right? Guideline adoption is literally how trial results become first-line prescribing at scale. And none of that has moved.
Ryan Castillo: And the number that matters here is 52%. Biktarvy's market share. With 7% revenue growth in 2025. While VOGUE was running.
Jordan Hale: While the trial was literally enrolling patients, Gilead was accelerating. That's not a company bracing for competition — that's a company that hasn't felt it yet.
Ryan Castillo: And Dovato's been approved since 2019. Nearly seven years of real-world evidence before VOGUE even reported. The needle hasn't shifted.
Jordan Hale: Seven years. You know what that tells me? One clean Phase IIIb trial doesn't override accumulated comfort. ViiV is the challenger here — GSK owning the majority of ViiV doesn't change the fact that the prescribing world still defaults to Gilead.
Ryan Castillo: Right — but the part that complicates this further is what else got announced at AIDS 2026. We'll get into it, but ISL/LEN enters the picture and the 'simplification' argument ViiV is making starts looking a lot less clean.
Jordan Hale: Yeah — and that's, I mean, that's actually the part that's been gnawing at me since I landed and closed the laptop. Because structural inertia is one problem. What's coming next might be a different one entirely.
Ryan Castillo: ISL/LEN isn't a rumor. At AIDS 2026, same conference, same week ViiV is taking a bow on VOGUE, Gilead and Merck stand up and announce Phase III data for islatravir/lenacapavir. Once-weekly. Oral. Two drugs. Non-inferiority also met.
Jordan Hale: Wait — same room, same week?
Ryan Castillo: Same conference. And look, the pipeline logic that follows is almost too clean — three daily drugs, then two daily drugs, now one dose per week of two drugs. That's not gradual progress, that's the floor moving.
Jordan Hale: So Dovato just finished proving two-drug daily works — and the reply from the room was, like... 'great, here's once a week.' That's a brutal moment to be ViiV's marketing team. I mean, Jean van Wyk, their CMO, just quoted results she probably spent years building toward, and Gilead immediately shifted the conversation.
Ryan Castillo: That's the rug-pull. Dovato's claim was simplification — one fewer drug every single day for decades. ISL/LEN makes that claim sound incremental. You're not simplifying to daily anymore, you're simplifying to weekly.
Jordan Hale: And that compounds, you know, in a very real human way. Picture someone who travels constantly — let's say a flight attendant managing HIV for thirty years. Two pills a day is better than three. But one pill a week? That's a different relationship with the medication entirely. Dovato doesn't get to claim that.
Ryan Castillo: Which means ViiV's marketing window — the moment where Dovato is the simplification leader — might close before it fully opens. VOGUE gives them a first-of-its-kind head-to-head win, but if ISL/LEN reaches approval first, Dovato isn't the destination. It's the middle chapter.
Jordan Hale: The middle chapter. That's — I mean, that actually stings a little. Seven years of real-world data, one landmark trial, and you might have proven your case right as the goalposts moved to weekly dosing.
Ryan Castillo: And then underneath all of that — the ISL/LEN announcement, the market share, the guideline lag — there's a number that just sits there. Global HIV funding down roughly 20% in the past year. A lot of that traced back to U.S. foreign aid cuts under the Trump administration.
Jordan Hale: Beatriz Grinsztejn said it out loud. President of the International AIDS Society, standing at AIDS 2026 in Rio, same conference where all this clinical progress was being celebrated — and she said HIV progress is in real danger. Not at risk, not under pressure. Danger.
Ryan Castillo: Better tools. Shrinking reach.
Jordan Hale: That's the thing I keep — I mean, you opened this by saying you were already skeptical. And I came in wanting to tell you the VOGUE story, the two-drug story. But I think... the actual image from that week in Rio is researchers presenting, you know, the most advanced HIV trial data maybe ever assembled in one place, in a city where the funding to put those drugs in people's hands is actively evaporating. That's not a policy footnote. That's the whole thing.
Ryan Castillo: You said you read the VOGUE headline three times on the plane thinking you were misreading it. I think the version of that headline that's harder to read is: two drugs just matched three, and we may not be able to afford to find out if it matters.
Jordan Hale: Yeah. That's where this one lands for me.
